EXABLATE 2100

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed with the FDA on 2017-08-29 for EXABLATE 2100 manufactured by Insightec, Ltd.

Event Text Entries

[83949599] The review of the device log files showed that the device performed according its specifications and no malfunctions occurred during the treatment. The patient's treatment log and the mr images were also thoroughly reviewed and no treatment anomalies that could be directly attributed to this event. During the treatment there were no user stopped sonication events. Since the device performed as intended and no anomalies were noted in the treatment file, we can only speculate as to the cause of this event. However, calculating the energy density (ed) on the bone and comparing to 5 references of uf cases (which did not end with any ae) showed no difference in the ed levels. In addition, based on our extensive experience with sacral bone sonication, patients report discomfort when such nerve is "excited" by the sonication that may be heating the bone. However, we would expect the same thing here; i. E. Patient would have reported some discomfort right away. Other medical conditions, such as reported conditions of tarlov cyst or myalgic encephalomyelitis may also affect the patient. It should be noted also that patient positioning may also exacerbate underlying conditions. The device risk management for the uterine fibroid application includes the risk associated with sacral bone (i. E. May induce nerve "stimulation" leading to sacral nerve leg pain, etc. ) and with heating bone in general. According to all the data collected from our treating sites, up to date, more than 13,000 uf patients were treated and the risk for neurological damage is 0. 08%. Note: date of this report is based on insightec's retrospective analysis of complaints
Patient Sequence No: 1, Text Type: N, H10


[83949600] Site reported that post treatment, the patient was found to have leg weakness confirmed via physical evaluation post mrgfus treatment for fibroid. Approximately one month later ((b)(6) 2016) the patient reported of slight improvement although she still has weakness in the right leg and thigh plus and has pain present in her groin and upper thigh. She reported that she was attending physio therapy. On the (b)(6) 2016 she reported that she had seen a neurologist and there is potential obturator nerve damage. He prescribed rest, no physio no exercise, no walking etc. For 6 weeks and prescribed prednisolone (steroid) and pregabalin for nerve pain relief. On (b)(6) 2017 the treating physician indicated that the patient has had nerve conduction tests an is still symptomatic.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number9615058-2017-00001
MDR Report Key6829278
Date Received2017-08-29
Date of Report2017-08-28
Date of Event2016-10-20
Date Facility Aware2017-01-23
Date Mfgr Received2017-01-23
Device Manufacturer Date2014-03-01
Date Added to Maude2017-08-29
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMR. IDAN COHEN
Manufacturer Street5 NACHUM HETH STREET P.O. BOX 2039
Manufacturer CityTIRAT CARMEL, ISRAEL 39120
Manufacturer CountryIS
Manufacturer Postal39120
Manufacturer G1INSIGHTEC, LTD
Manufacturer Street5 NACHUM HETH STREET P.O. BOX 2039
Manufacturer CityTIRAT CARMEL, ISRAEL 39120
Manufacturer CountryIS
Manufacturer Postal Code39120
Single Use3
Previous Use Code3
Event Type3
Type of Report0

Device Details

Brand NameEXABLATE 2100
Generic NameMR-GUIDED FOCUSED ULTRASOUND
Product CodePOH
Date Received2017-08-29
Model Number2100
OperatorHEALTH PROFESSIONAL
Device AvailabilityY
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerINSIGHTEC, LTD
Manufacturer Address5 NACHUM HETH STREET P.O. BOX 2039 TIRAT CARMEL, ISRAEL 39120 IS 39120


Patients

Patient NumberTreatmentOutcomeDate
101. Congenital Not Applicablenomaly; 2. Other; 3. Required No Informationntervention 2017-08-29

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.